Discovery of CP-533536: An EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 7, 2009, Pages 2075-2078

  Cameron, Kimberly O ^a   Lefker, Bruce A ^a   Ke, Hua Z ^b   Li, Mei ^a   Zawistoski, Michael P ^a   Tjoa, Christina M ^a   Wright, Ann S ^a   DeNinno, Shari L ^a   Paralkar, Vishwas M ^a   Owen, Thomas A ^c   Yu, Li ^d   Thompson, David D ^a  

^a PFIZER INC   (United States)

^b AMGEN INC   (United States)

^c RAMAPO COLLEGE OF NEW JERSEY   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bone; EP2 receptor; Fracture healing; Prostaglandin

Indexed keywords

[3 [[(4 TERT BUTYLBENZYL)(3 PYRIDINESULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; FRACTURE; FRACTURE HEALING; MALE; NONHUMAN; OSSIFICATION; RAT; SINGLE DRUG DOSE;

ANIMALS; MALE; OSTEOGENESIS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

RATTUS;

EID: 61849108824     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.059     Document Type: Article

References (15)

1. Jee W.S., and Ma Y.F. Bone 21 (1997) 297-304
2. Marks Jr. S.C., and Miller S.C. Endocr. J. 1 (1993) 337-344
3. Ke H.Z., Shen V.W., Qi H., Crawford D.T., Wu D.D., Liang X.G., Chidsey-Frank K.L., Pirie C.M., Simmons H.A., and Thompson D.D. Bone 23 (1998) 239
4. Raisz L.G. Clin. Rev. 4 (2006) 123
5. Zaidi M., Zaidi N., and Sun L. Drugs Future 32 (2007) 833
6. Cameron K.O., Lefker B.A., Chu-Moyer M.Y., Crawford D.T., DaSilva-Jardine P., DeNinno S.L., Gilbert S., Grasser W.A., Ke H., Lu B., Owen T.A., Paralkar V.M., Qi H., Scott D.O., Thompson D.D., Tjoa C.M., and Zawistoski M.P. Bioorg. Med. Chem. Lett. 16 (2006) 1799-1802
7. Paralkar V.M., Borovecki F., Ke H.Z., Cameron K.O., Lefker B.A., Grasser W.A., Qi H.L., Owen T.A., Li M., DaSilva-Jardine P., Dumont F., Korsmeyer R., Krasney P., Brown T.A., Plowchalk D., Vukicevic S., and Thompson D.D. Proc. Nat. Aacd. Sci. 100 (2003) 6736
8. Li M., Ke H.Z., Hong Q., Healy D., Li Y., Crawford T., Paralkar V., Owen T.A., Cameron K.O., Lefker B.A., Brown T.A., and Thompson D.D. J. Bone Min. Res 18 (2003) 2033
9. Cameron, K. O.; Lefker, B. A.; Rosati, R. L. U.S. Patent 6,498,172, 1999.
10. Lefker, B. A.; Cameron, K. O.; Crawford, D. T.; DaSilva-Jardine, P. A.; DeNinno, S. L.; Gao, H.; Grasser, W. A.; Ebbinghaus, C. F.; Healy, D. R.; Elliott, N. C.; Ke, H. Z.; Li, M.; Lu, B.; Owen, T. A.; Paralkar, V. M.; Qi, H.; Rosati, R. L.; Tjoa, C. M.; Wright, A. S.; Yu, L.; Zawistoski, M. P.; Thompson, D. D. Abstracts of Papers, 224th National Meeting of the American Chemical Society, Boston, MA, 2002; Abstract MEDI-370.
11. Jones J.H., Holtz W.J., Bicking J.B., Cragoe Jr. E.J., Mandel L.R., and Kuehl F.A. J. Med. Chem. 20 (1977) 1299
12. All procedures were reviewed and approved by the Institutional Animal Care & Use Committee.
13. 4 cell line. Rat in vitro data was collected because we used rat as our pre-clinical efficacy model.
14. Atrix Laboratories, Inc., Fort Collins, CO.
15. Ke H.Z., Qi H., Chidsey-Frank K.L., Crawford D.T., and Thompson D.D. J. Bone Miner. Res. 16 (2001) 765